文献速递结核与非结核分枝杆菌

耐多药结核病患者的长期治疗结局

Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
PubMed 文献 · Clin Microbiol Infect · 2023-02-25

在德国一家耐多药/利福平耐药结核病(MDR/RR-TB)转诊中心,对2002年9月1日至2020年2月29日收治的163例患者进行个体化随访,比较WHO-2013、WHO-2021和结核病网络欧洲试验组-2016定义下的治疗结局。长期无复发治愈率为62.0%(101/163),高于各定义下的治愈率。

要点

  • 长期无复发治愈101/163(62.0%),已知状态者中101/122(82.8%)。
  • 按WHO-2013、WHO-2021和TBNET-2016定义,治愈分别为25/163(15.3%)、82/163(50.3%)和95/163(58.3%)。
  • HIV感染者死亡风险比4.28(95%CI 1.26-12.86),年龄每增1岁风险比1.08(95%CI 1.05-1.12)。

核心结论

  • 在采用个体化治疗方案的优化管理条件下,MDR/RR-TB的长期无复发治愈率显著高于现行治疗结局定义所界定的治愈率。

研究设计与样本

  • 研究纳入2002年9月1日至2020年2月29日德国一家MDR/RR-TB转诊中心的163例MDR/RR-TB患者,比较个体化随访的长期治疗结局与WHO-2013、WHO-2021及结核病网络欧洲试验组-2016定义下的结局。

主要发现

  • 163例患者平均年龄35岁(标准差13岁),14/163(8.6%)合并HIV感染,109/163(66.9%)为男性,149/163(91.4%)在5年内移民至德国。
  • 15/163(9.2%)菌株对氟喹诺酮类或二线注射剂耐药,29/163(17.8%)菌株对两类药物均耐药。
  • MDR/RR-TB治疗中位时长20个月(四分位距19.3-21.6个月),中位使用5种活性药物。
  • 中位随访时间4年(47.7个月;四分位距21.7-65.8个月);失访率17/163(10.4%)。
  • 按WHO-2013、WHO-2021和结核病网络欧洲试验组-2016定义,治愈分别为25/163(15.3%)、82/163(50.3%)和95/163(58.3%);长期无复发治愈101/163(62.0%),已知状态者中101/122(82.8%)。

关键数值与推荐

  • HIV感染者死亡风险比4.28(95%CI 1.26-12.86);年龄每增加1岁死亡风险比1.08(95%CI 1.05-1.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe long-term treatment outcomes in patients with multi-drug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) and validate established outcome definitions for MDR/RR-TB treatment. METHODS: Among patients with MDR/RR-TB admitted to a German MDR/RR-TB referral centre from 1 September 2002 to 29 February 2020, we compared long-term treatment outcomes derived from individual patient follow-up with treatment outcomes defined by WHO-2013, WHO-2021 and the Tuberculosis Network European Trials Group-2016. RESULTS: In a total of 163 patients (mean age, 35 years; standard deviation, 13 years; 14/163 [8.6%] living with HIV; 109/163 [66.9%] men, 149/163 [91.4%] migrating to Germany within 5 years), the treatment of culture-confirmed MDR/RR-TB was initiated. Additional drug resistance to a fluoroquinolone or a second-line injectable agent was present in 15 of the 163 (9.2%) Mycobacterium tuberculosis strains; resistance against both the drug classes was present in 29 of the 163 (17.8%) strains. The median duration of MDR/RR-TB treatment was 20 months (interquartile range, 19.3-21.6 months), with a medium of five active drugs included. The median follow-up time was 4 years (47.7 months; interquartile range, 21.7-65.8 months). Among the 163 patients, cure was achieved in 25 (15.3%), 82 (50.3%) and 95 (58.3%) patients according to the outcome definitions of WHO-2013, WHO-2021, and the Tuberculosis Network European Trials Group-2016, respectively. The lost to follow-up rate was 17 of 163 (10.4%). Death was more likely in patients living with HIV (hazard ratio, 4.28; 95% confidence interval, 1.26-12.86) and older patients (hazard ratio, 1.08; 95% confidence interval, 1.05-1.12; increment of 1 year). Overall, 101/163 (62.0%) patients experienced long-term, relapse-free cure; of those, 101/122 (82.8%) patients with a known status (not lost to-follow-up or transferred out) at follow-up. CONCLUSION: Under optimal management conditions leveraging individualized treatment regimens, long-term, relapse-free cure from MDR/RR-TB is substantially higher than cure rates defined by current treatment outcome definitions.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Maier C, Chesov D, Schaub D, et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin Microbiol Infect. 2023. PMID: 36842637. doi:10.1016/j.cmi.2023.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。